Scientists in China have used a next-generation form of CRISPR genome-editing to repair a disease-causing mutation in human embryos, the first use of the technique in viable embryos that were created by a standard fertility clinic technique.
The study is a notable advance over previous attempts to edit human embryos and brings closer the day when genome editing might be used to alter the DNA of early-stage IVF embryos in such a way that the changes would be inherited by subsequent generations, potentially wiping out diseases caused by single genetic mutations.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
